May. 16 at 9:20 AM
$IFRX Interesting CHEST article behind a paywall about STSA-1002 (phase 1b/2 in viral pneumonia/ARDS). According to the text, this is an anti-C5a approach with noticeable mortality data in the high-dose group, even though the patient numbers were still small and the authors remain cautious.
A total of 49 patients were enrolled. The 28-day mortality according to the article was:
5.88% in the STSA-1002 1350mg group
26.67% in the STSA-1002 750mg group
40% under placebo
The main inclusion criterion was a PaO2/FiO2 ≤ 200 mmHg, which is a measure of already severe oxygen impairment in ARDS. Compared to GOHIBIC, this study appears broader according to the text and not limited only to the most critically ventilated COVID patients.
The authors therefore describe a “favorable safety profile and potential efficacy”, while also emphasizing that this still needs to be confirmed in a phase 3 trial.
Interestingly, “IFX-1 (vilobelimab)” is explicitly mentioned in the abbreviation list.
https://journal.chestnet.org/article/S0012-3692(26)00638-0/abstract
